Why must hydroxychloroquine continue in primary Sjögren's syndrome after dry eyes and dry mouth improve?

The most dangerous hydroxychloroquine adherence error in primary Sjögren's syndrome with peripheral neuropathy is stopping the drug when glandular symptoms improve — dry eyes less severe, artificial tears less needed, dry mouth less prominent — reasoning that the most visible features of Sjögren's have been controlled. This reasoning correctly identifies a real benefit of hydroxychloroquine in glandular Sjögren's. It fatally misidentifies the lacrimal gland as the totality of what HCQ is protecting in a patient who also has peripheral nervous system involvement. The two anatomical compartments — lacrimal gland and dorsal root ganglia — are completely separate targets of anti-Ro52/SSA autoimmunity, and HCQ's protective effects in one compartment have no bearing on the status of the other. Hydroxychloroquine works by accumulating in lysosomes and raising lysosomal pH, impairing TLR7 and TLR9 endosomal recognition of RNA-containing immune complexes including the RNA components of Ro52 and Ro60 antigens. This reduces MyD88-IRF7-IFN-alpha signaling in plasmacytoid dendritic cells and B cells, and suppresses the plasmablast differentiation program that maintains anti-Ro52/SSA IgG production. Under sustained HCQ therapy, anti-Ro52/SSA titers typically fall over twelve to twenty-four months. In the lacrimal gland, reduced anti-Ro52/SSA and reduced IFN-alpha-driven lymphocytic infiltration produces measurable glandular benefit: improved Schirmer's test, reduced need for artificial tears. This is the effect the patient sees and attributes to recovery. In patients with peripheral nervous system involvement, the more critical protective action of HCQ is in a completely different anatomical location. Primary Sjögren's peripheral neuropathy most commonly takes the form of sensory ganglionopathy — destruction of the sensory neuron cell bodies in the dorsal root ganglia, the clusters of large sensory neurons adjacent to the spinal cord that give rise to all peripheral sensory axons. The critical anatomical fact is that the dorsal root ganglia lack the tight-junction blood-nerve barrier that protects peripheral nerve trunks from circulating proteins. This means DRG sensory neuron cell bodies are directly exposed to serum components including anti-Ro52/SSA IgG. Anti-Ro52/SSA IgG binding to DRG neuron surface antigens activates complement through the classical pathway — C1q recognizes anti-Ro52/SSA-antigen complexes on the neuronal soma, activating C4 and C2 to produce C3 convertase, then C5 convertase, assembling the membrane attack complex (C5b-C6-C7-C8-C9) on the DRG neuron plasma membrane. MAC formation produces irreversible ion channel disruption and osmotic lysis of the DRG sensory neuron. The clinical consequence is progressive length-dependent sensory axonopathy: since DRG neurons give rise to peripheral sensory axons that run distally, the death of DRG neuron cell bodies produces a dying-back sensory neuropathy — first affecting the longest axons (vibration and proprioception at the ankles and feet) and then progressing proximally. The critical irreversibility: mature DRG neurons in humans do not regenerate. Once a DRG sensory neuron cell body is destroyed by complement-mediated MAC formation, the sensory axon it supported cannot be replaced. The sensory deficit is permanent. What hydroxychloroquine does in this context is suppress the TLR7/9-IFN-alpha-plasmablast axis that maintains the anti-Ro52/SSA titer — reducing the circulating antibody available to form complement complexes at the DRG. This is a preventive action: it does not regenerate destroyed neurons but it slows the ongoing destruction of surviving neurons. When HCQ is stopped because Schirmer's test improved, the lacrimal gland provides the feedback for the decision. The DRG provides no feedback — there are no early warning symptoms of DRG neuron destruction until a substantial fraction of sensory neurons in a given segment has been lost. The DRG neuropathy may progress for twelve to twenty-four months before the patient or clinician recognizes that the sensory loss is worsening. By that point the DRG neuron losses are irreversible. Spanish frame for the Sjögren's extraglandular nurse: 'El hidroxicloroquina está protegiendo dos cosas al mismo tiempo, y solo una de ellas se puede ver. Lo que se ve es que sus ojos producen más lágrimas — eso es real, y es una buena señal. Lo que no se puede ver es lo que el medicamento está haciendo en un lugar completamente diferente: en los ganglios de las raíces dorsales, que son grupos de neuronas sensoriales que están junto a la columna vertebral y de las cuales salen todos los nervios que le permiten sentir vibración, posición, temperatura y toque en las piernas y pies. Los anticuerpos anti-Ro52 en su enfermedad pueden unirse a esas neuronas y activar el sistema de complemento — una cascada de proteínas que destruyen la membrana de la neurona. Cuando esas neuronas mueren, no se recuperan. Nunca. El medicamento reduce la cantidad de anticuerpos en circulación, lo que ralentiza ese proceso de destrucción neuronal. Que sus ojos estén mejor no significa que esas neuronas estén protegidas sin el medicamento — son lugares distintos en el cuerpo, con mecanismos distintos. Para el hormigueo, la vibración y el equilibrio, el medicamento debe continuar.' (Hydroxychloroquine is protecting two things simultaneously, and only one of them can be seen. What is visible is that your eyes produce more tears — that is real, and it is a good sign. What cannot be seen is what the medication is doing in a completely different location: in the dorsal root ganglia, which are clusters of sensory neurons alongside the spinal cord from which all the nerves that allow you to feel vibration, position, temperature, and touch in the legs and feet originate. The anti-Ro52 antibodies in your disease can bind to those neurons and activate the complement system — a cascade of proteins that destroys the neuron's membrane. When those neurons die, they do not recover. Ever. The medication reduces the amount of circulating antibodies, which slows that process of neuronal destruction. The fact that your eyes are better does not mean those neurons are protected without the medication — they are different locations in the body with different mechanisms. For the tingling, vibration, and balance, the medication must continue.)

Why must rituximab continue in Sjögren's syndrome cryoglobulinemic vasculitis after anti-SSA/Ro antibody titers fall?

The most consequential rituximab adherence error in Sjögren's syndrome with type II mixed cryoglobulinemia is self-discontinuation when anti-Ro52/SSA antibody titers fall significantly during treatment, reasoning that if the antibodies that define Sjögren's are nearly absent, the disease must be in remission. This reasoning correctly identifies a real benefit of rituximab — it depletes CD20-positive B cells including the mainstream polyclonal B cells producing anti-Ro52/SSA — but it misunderstands the relationship between anti-Ro52 titer and the cryoglobulinemic vasculitis mechanism in Sjögren's. Type II mixed cryoglobulinemia in Sjögren's is not driven by anti-Ro52/SSA antibodies themselves. It is driven by a distinct clonal B cell population: a MALT-like lymphoplasmacytoid expansion producing monoclonal IgM-kappa rheumatoid factor. This clonal expansion arises primarily in the mucosa-associated lymphoid tissue of Sjögren's-damaged salivary glands — the periductal lymphoid aggregates that form in response to chronic ductal epithelial antigen presentation — and in draining lymph nodes and spleen. The MALT clone is stimulated by two inputs: chronic BCR engagement with anti-Ro52 antigen-antibody immune complexes (which stimulate the BCR on IgM-kappa-producing B cells through shared idiotype interactions) and CD40L-CD40 T helper cell collaboration from anti-Ro52-specific CD4-positive T cells. This clonal B cell population produces monoclonal IgM-kappa with rheumatoid factor specificity — IgM-kappa that binds to the Fc region of IgG molecules. In cold temperatures, IgM-kappa rheumatoid factor forms insoluble immune complexes with IgG (the cryoprecipitate), depositing in small vessel walls and activating complement and triggering leukocytoclastic vasculitis, palpable purpura, digital ischemia, and membranoproliferative glomerulonephritis. Rituximab depletes CD20-positive B cells. Mainstream polyclonal B cells producing anti-Ro52/SSA are CD20-positive and are depleted efficiently, explaining the fall in anti-Ro52 titer observed during rituximab treatment. The IgM-kappa MALT clone contains cells at various stages of lymphoplasmacytoid differentiation: early B cells are CD20-positive and are depleted by rituximab; late-stage plasma cells and lymphoplasmacytoid cells may be CD20-low or CD20-negative and partially escape rituximab depletion, persisting in MALT niches protected from circulating rituximab by their tissue-resident microenvironment. The critical difference in reconstitution kinetics: mainstream polyclonal B cells reconstitute from CD20-negative bone marrow B cell precursors over six to twelve months after rituximab depletion — these precursors must undergo the full developmental sequence (pro-B, pre-B, immature B, transitional B, mature naive B) before producing antibody. The IgM-kappa MALT clone reconstitutes from partially depleted MALT-resident progenitors that retain some proliferative capacity, can begin producing IgM-kappa cryoglobulin within weeks of rituximab plasma levels falling below the threshold for sustained B cell depletion, and in some patients reconstitutes substantially before anti-Ro52 titers rise in serum. This creates the clinically paradoxical pattern of falling or stably suppressed anti-Ro52 titer with rising cryocrit and rising rheumatoid factor titer — which is exactly what the nurse will see in the patient who self-stops rituximab reasoning the antibodies are under control. The cryoglobulinemic nephritis driven by resuming MALT clone IgM-kappa production can progress rapidly: membranoproliferative GN with mesangial and subendothelial IgM-kappa deposits can produce a serum creatinine rise of one to two milligrams per deciliter within four to eight weeks of MALT clone reconstitution, while anti-Ro52 titers remain suppressed because mainstream B cells are still depleted. Waiting for anti-Ro52 to rise as the signal to restart rituximab means the cryoglobulinemic nephritis has been progressing for weeks before the conventional marker signals relapse. Maintenance rituximab in Sjögren's cryoglobulinemic vasculitis is typically every six months, with treatment decisions based on cryocrit trend, rheumatoid factor titer, purpura recurrence, and renal function — not anti-Ro52/SSA titer alone. Spanish frame: 'El anticuerpo anti-SSA que bajó significa que el rituximab está eliminando un grupo de células B del sistema inmune que producen ese anticuerpo. Eso es bueno. Pero la vasculitis — las manchas moradas en las piernas, las úlceras en los dedos, el daño en el riñón — no la produce directamente ese anticuerpo. La produce otro grupo de células B que es diferente: una especie de clon que se formó en las glándulas salivales cuando éstas se dañaron con la enfermedad, y que produce un anticuerpo diferente — IgM-kappa — que en frío forma complejos que se depositan en los vasos pequeños y los inflaman. Ese clon vuelve a crecer después del rituximab más rápido que el otro grupo de células B, incluso cuando el anti-SSA todavía está bajo. Por eso el marcador de la vasculitis — el criocrito, el factor reumatoide — puede subir mientras el anti-SSA sigue bajo. Si para el rituximab porque el anti-SSA bajó, el clon que produce la vasculitis puede reactivarse antes de que el anti-SSA suba — y el daño renal de esa reactivación puede ser parcialmente permanente. El rituximab de mantenimiento cada seis meses es lo que controla ese clon. Que el anti-SSA esté bajo es una buena señal — no una señal de que puede parar.' (The anti-SSA antibody that fell means rituximab is eliminating one group of B cells that produce that antibody. That is good. But the vasculitis — the purple spots on the legs, the ulcers on the fingers, the kidney damage — is not produced directly by that antibody. It is produced by a different group of B cells: a kind of clone that formed in the salivary glands when they were damaged by the disease, and that produces a different antibody — IgM-kappa — that in cold forms complexes that deposit in small vessels and inflame them. That clone grows back after rituximab faster than the other group of B cells, even when anti-SSA is still low. That is why the marker of vasculitis — the cryocrit, the rheumatoid factor — can rise while anti-SSA remains low. If you stop rituximab because anti-SSA fell, the clone that produces the vasculitis can reactivate before anti-SSA rises — and the kidney damage from that reactivation can be partially permanent. The maintenance rituximab every six months is what controls that clone. The anti-SSA being low is a good sign — not a sign that you can stop.)

Why must azathioprine continue in Sjögren's-associated interstitial lung disease after anti-Ro52/SSA titers fall and pulmonary function tests stabilize?

The most consequential azathioprine adherence error in Sjögren's-associated interstitial lung disease is discontinuation when anti-Ro52/SSA antibody titers fall significantly and pulmonary function tests remain stable, reasoning that if the autoantibodies have nearly normalized and the lung tests show no deterioration, the disease must be under control and the immunosuppressant can be safely stopped. This reasoning misunderstands both the mechanism of azathioprine in Sjögren's ILD and the relationship between antibody titers and the alveolar fibrogenic process that determines long-term lung function. Azathioprine works through inhibition of inosine monophosphate dehydrogenase — the rate-limiting enzyme in de novo guanine nucleotide synthesis. Lymphocytes depend almost entirely on de novo purine synthesis for clonal expansion. IMDH inhibition by azathioprine's active metabolites depletes GTP and ATP in both T cells and B cells. B cell suppression reduces anti-Ro52/SSA plasmablast differentiation and lowers the antibody titer — the laboratory change the patient sees. T cell suppression restrains the CD4-positive T cell alveolar infiltration that is the upstream driver of Sjögren's-associated ILD. In the nonspecific interstitial pneumonia pattern that characterizes Sjögren's ILD, U1-snRNP-reactive and anti-Ro52-associated T helper cells traffic through alveolar capillaries and extravasate into the alveolar interstitium, where they present self-antigens to tissue-resident alveolar macrophages through antigen-peptide-MHC class II interactions and activate them through IL-4, IL-13, and IL-21 cytokine signaling. This activation drives alveolar macrophage polarization toward the M2 phenotype, which produces TGF-beta-one as its primary effector cytokine. TGF-beta-one binds TGF-beta receptor II on alveolar epithelial type II cells and lung fibroblasts, activating SMAD2 and SMAD3 phosphorylation and driving transcription of alpha-smooth muscle actin, fibronectin, vimentin, and type I and type III collagen — the markers of myofibroblast differentiation. Myofibroblasts contract the alveolar interstitium, deposit collagen matrix, and stiffens lung tissue, producing the reduced FVC and DLCO characteristic of ILD progression. The critical feature that makes antibody titer monitoring an inadequate proxy for fibrogenic activity is myofibroblast autonomy. Once lung fibroblasts have differentiated into myofibroblasts under sustained TGF-beta signaling, they establish a self-sustaining autocrine TGF-beta production loop: activated myofibroblasts release latent TGF-beta into the extracellular matrix; matrix metalloproteinase-2 and -9 (produced by myofibroblasts themselves) cleave the latency-associated peptide from latent TGF-beta, releasing active TGF-beta-one; this active TGF-beta-one binds myofibroblast TGF-beta receptor II in an autocrine loop, sustaining SMAD2/3 phosphorylation and myofibroblast maintenance largely independently of continued T cell or B cell activation. The practical consequence: stable FVC and DLCO on azathioprine do not mean the fibrogenic potential of the lung has been eliminated. They mean azathioprine is restraining the T cell alveolar infiltration that feeds new TGF-beta signal into the existing myofibroblast population. When azathioprine is stopped, B cell suppression is removed and anti-Ro52 titers will begin recovering — but the more immediately consequential change is the removal of T cell suppression. CD4-positive T cell infiltration of the alveolar interstitium resumes before anti-Ro52 titers rise significantly in serum, because T cell alveolar trafficking does not require antibody and because peripheral T cell recovery from azathioprine withdrawal is faster than B cell differentiation from bone marrow precursors. The T cell-M2 macrophage-TGF-beta axis reactivates, and the established myofibroblast population — still present and primed by the ongoing autocrine TGF-beta loop — now receives additional TGF-beta signal from newly activated macrophages. FVC and DLCO decline faster than they would have under continued azathioprine. The FVC and DLCO losses during the off-azathioprine period are not recovered when azathioprine is restarted, because myofibroblast-mediated fibrosis produces irreversible collagen cross-linking. This is the therapeutic asymmetry of Sjögren's ILD: azathioprine must be continued to prevent new losses; it cannot recover losses that occurred during a treatment gap. The minimum treatment duration in Sjögren's-associated ILD is typically two to three years from first diagnosis with continued therapy past antibody normalization; any dose reduction should be guided by PFT stability over at least twelve months and HRCT stability, not antibody titer. Spanish frame: 'El azatioprina está haciendo dos cosas al mismo tiempo, y solo una de ellas se ve en los análisis de sangre. Lo que se ve es que el anticuerpo anti-Ro52 ha bajado — eso indica que el medicamento está suprimiendo las células B que producen ese anticuerpo. Pero el daño en el pulmón no lo producen directamente esos anticuerpos. Lo producen las células T, que llegan al pulmón y activan los macrófagos, que producen TGF-beta, que convierte células normales del tejido pulmonar en células cicatriciales — se llaman miofibroblastos — que depositan colágeno y reducen la capacidad del pulmón. Una vez que esas células cicatriciales existen, producen su propia señal TGF-beta de manera casi independiente. El azatioprina frena las células T que alimentan ese proceso. Que la espirometría esté estable es precisamente la prueba de que el medicamento está funcionando — no una señal de que puede parar. Si para el azatioprina porque el anticuerpo bajó y la espirometría está estable, las células T vuelven al pulmón antes de que el anticuerpo suba de nuevo, y la función pulmonar que se pierde en ese tiempo — la caída en la espirometría y la DLCO — no se recupera cuando se reinicia el medicamento. El colágeno que se deposita en ese período es permanente. La meta es que la espirometría no caiga, y eso requiere que el medicamento continue.' (Azathioprine is doing two things simultaneously, and only one of them is visible in blood tests. What is visible is that the anti-Ro52 antibody has fallen — that indicates the medication is suppressing the B cells that produce that antibody. But the damage in the lung is not produced directly by those antibodies. It is produced by T cells, which travel to the lung and activate macrophages, which produce TGF-beta, which converts normal lung tissue cells into scar cells — called myofibroblasts — that deposit collagen and reduce lung capacity. Once those scar cells exist, they produce their own TGF-beta signal almost independently. Azathioprine slows the T cells that feed that process. The fact that spirometry is stable is precisely the proof that the medication is working — not a sign that you can stop. If you stop azathioprine because the antibody fell and spirometry is stable, T cells return to the lung before the antibody rises again, and the lung function lost in that time — the fall in spirometry and DLCO — is not recovered when the medication is restarted. The collagen deposited in that period is permanent. The goal is for spirometry not to fall, and that requires the medication to continue.)

What is Sjögren's syndrome dorsal root ganglionopathy and how do extraglandular clinic nurses explain it in Spanish?

Sjögren's syndrome dorsal root ganglionopathy — also called sensory ganglionopathy or sensory neuronopathy — is the most common form of Sjögren's peripheral neuropathy and one of the most consequential extraglandular manifestations because it produces irreversible sensory disability that can progress to sensory ataxia and falls if not prevented. The pathological mechanism is distinct from the more common inflammatory peripheral neuropathies: rather than damaging the axon or the myelin sheath in peripheral nerves, Sjögren's ganglionopathy destroys the sensory neuron cell body itself in the dorsal root ganglia. The DRG are unique in the peripheral nervous system because they lack the tight-junction blood-nerve barrier that protects axons in peripheral nerve trunks from circulating blood proteins. DRG neuron cell bodies are bathed in a fenestrated capillary network that allows free diffusion of serum immunoglobulins and complement proteins. This anatomical vulnerability makes the DRG directly accessible to circulating anti-Ro52/SSA IgG, which binds to DRG neuron cell body surface antigens through cross-reactive epitopes, activates the classical complement pathway, and produces membrane attack complex formation on the neuron plasma membrane — an irreversible cellular destruction event. Because DRG sensory neurons in humans are mature post-mitotic cells that do not undergo significant regeneration after destruction, the sensory deficit is permanent and length-dependent: the longest peripheral sensory axons (those supplying vibration and proprioception at the ankles and feet) are affected first because their cell bodies in the DRG are destroyed and those axons cannot be replaced. As more DRG neurons in successively proximal levels are destroyed, the vibration loss, hypoesthesia, and proprioceptive loss extends proximally from the feet to the lower legs, then the thighs. Loss of proprioception in the lower extremities produces sensory ataxia — an unsteady, wide-based gait with positive Romberg sign (inability to stand steady with eyes closed) — because proprioception is what the cerebellum uses to monitor lower limb position in space without visual feedback. The severity of the sensory ataxia can progress to requiring a cane, then a walker, and in advanced cases wheelchair dependency, entirely from the somatosensory deficit without any motor involvement. Sjögren's ganglionopathy is detected by nerve conduction studies showing absent or markedly reduced sensory nerve action potential amplitudes in a non-length-dependent pattern (all sensory nerves affected rather than longest first) — which the electromyographer will often report as a sensory neuronopathy pattern rather than the distal-predominant sensory neuropathy of metabolic or toxic causes. For the extraglandular Sjögren's clinic nurse explaining DRG ganglionopathy to Spanish-speaking patients, the key teaching points are: the hands and feet can feel different things with different clinical implications; the neuropathy is in the cell bodies not the nerve branches; the progression is irreversible once neurons are lost; and the treatment target is slowing the rate of ongoing destruction by reducing the circulating anti-Ro52 that activates complement at the DRG, not repairing damage that has already occurred. Spanish frame: 'En la enfermedad de Sjögren, además de los ojos y la boca, los anticuerpos pueden atacar las neuronas de los nervios sensoriales. Hay unos grupos de neuronas que se llaman ganglios de la raíz dorsal — están junto a la columna vertebral, y de ellas salen los nervios que le permiten sentir vibración, posición y toque en las piernas y pies. Estos ganglios tienen una característica especial: no tienen la barrera de protección que tienen los nervios normales, así que los anticuerpos pueden llegar directamente a las neuronas y, con la ayuda de otras proteínas del sistema inmune, destruir las membranas de esas neuronas. Cuando una neurona de ese tipo muere, no hay otra neurona que la reemplace — el nervio que salía de ella no puede regenerarse. Por eso cuando nota que tiene menos sensación de vibración o posición en los pies, o que el balance es peor, es una señal de que esas neuronas ya han sufrido daño. El tratamiento con HCQ no regenera las neuronas perdidas — las que se perdieron no vuelven — pero frena el proceso que destruye las que quedan. El objetivo es preservar lo que queda.' (In Sjögren's disease, in addition to the eyes and mouth, the antibodies can attack the neurons of the sensory nerves. There are clusters of neurons called dorsal root ganglia — they are alongside the spinal column, and from them emerge the nerves that allow you to feel vibration, position, and touch in the legs and feet. These ganglia have a special characteristic: they do not have the protective barrier that normal nerves have, so antibodies can reach the neurons directly and, with the help of other immune system proteins, destroy the membranes of those neurons. When one of those types of neurons dies, there is no other neuron to replace it — the nerve that emerged from it cannot regenerate. That is why when you notice that you have less sensation of vibration or position in the feet, or that your balance is worse, it is a sign that those neurons have already suffered damage. Treatment with HCQ does not regenerate the lost neurons — those that were lost do not return — but it slows the process that destroys the remaining ones. The goal is to preserve what remains.)

What are the key Spanish phrases for Sjögren's extraglandular manifestations clinic nurses explaining peripheral neuropathy, cryoglobulinemic vasculitis, and ILD medication continuation?

For explaining why hydroxychloroquine must continue in Sjögren's with peripheral neuropathy after dry eyes resolve: 'El hidroxicloroquina está protegiendo algo que no se puede ver: las neuronas sensoriales que están junto a la columna vertebral. Sus anticuerpos anti-Ro52 pueden unirse a esas neuronas y destruirlas con el complemento. Cuando esas neuronas mueren, no se recuperan — la vibración, la posición, el balance que dependen de ellas se pierden para siempre. El medicamento reduce los anticuerpos en la sangre y frena ese proceso. Que sus ojos estén mejor es una señal de que el medicamento funciona — pero los ojos y los nervios son lugares distintos y el medicamento debe continuar para proteger los dos.' (Hydroxychloroquine is protecting something that cannot be seen: the sensory neurons alongside the spinal cord. Your anti-Ro52 antibodies can bind to those neurons and destroy them with complement. When those neurons die, they do not recover — the vibration, position, and balance that depend on them are lost permanently. The medication reduces the antibodies in the blood and slows that process. The fact that your eyes are better is a sign that the medication works — but the eyes and the nerves are different locations and the medication must continue to protect both.) For explaining signs of neuropathy progression to monitor between visits: 'Si nota que siente menos vibración o temperatura en los pies — como si los pies estuvieran entumecidos o con calcetines aunque no lleve — comuníquese con la clínica. Si nota que su balance está peor al caminar en la oscuridad, o que necesita ver el suelo mientras camina para no tropezar, eso es una señal importante. Si cierra los ojos al ponerse de pie y siente que se va a caer, llame el mismo día.' (If you notice that you feel less vibration or temperature in the feet — as if the feet were numb or as if you were wearing socks even though you are not — contact the clinic. If you notice that your balance is worse walking in the dark, or that you need to look at the ground while walking to avoid tripping, that is an important sign. If you close your eyes while standing and feel that you are going to fall, call the same day.) For explaining why rituximab must continue in Sjögren's cryoglobulinemia after anti-SSA titer falls: 'El rituximab está eliminando dos tipos de células B — las que producen el anti-SSA y las que producen el factor reumatoide IgM-kappa que causa la vasculitis. El anti-SSA que bajó indica que el primer grupo está controlado. Pero el segundo grupo — el clon que produce la vasculitis y el daño renal — puede volver más rápido que el primero. Por eso el criocrito y el factor reumatoide son los marcadores que seguimos para la vasculitis, no el anti-SSA. Las infusiones de mantenimiento cada seis meses controlan ese clon. Si para el rituximab porque el anti-SSA bajó, el clon de la vasculitis puede volver antes de que el anti-SSA suba, y el daño renal de esa reactivación puede ser permanente.' (Rituximab is eliminating two types of B cells — those that produce anti-SSA and those that produce the IgM-kappa rheumatoid factor that causes vasculitis. The anti-SSA that fell indicates the first group is controlled. But the second group — the clone that produces the vasculitis and kidney damage — can return faster than the first. That is why the cryocrit and rheumatoid factor are the markers we follow for vasculitis, not anti-SSA. The maintenance infusions every six months control that clone. If you stop rituximab because anti-SSA fell, the vasculitis clone can return before anti-SSA rises, and the kidney damage from that reactivation can be permanent.) For explaining signs of cryoglobulinemic vasculitis recurrence to watch for: 'Si nota manchas moradas o rojas en las piernas — especialmente en la parte baja — que no desaparecen al presionarlas, llame a la clínica ese día. Si nota que dedos de las manos o los pies se ponen oscuros, fríos o dolorosos con el frío, llame. Si sus análisis muestran que la creatinina está subiendo o que hay proteína en la orina, eso puede ser la vasculitis en el riñón y requiere evaluación urgente.' (If you notice purple or red spots on the legs — especially the lower part — that do not disappear when pressed, call the clinic that day. If you notice that fingers or toes become dark, cold, or painful with cold, call. If your tests show that creatinine is rising or that there is protein in the urine, that may be vasculitis in the kidney and requires urgent evaluation.) For explaining Sjögren's ILD spirometry surveillance and azathioprine continuation: 'La espirometría que hacemos cada seis meses es la manera de saber si el tejido pulmonar está estable. Mientras el número se mantenga o mejore, es señal de que el tratamiento está funcionando. Si el número cae — aunque no sienta diferencia — es la señal para ajustar antes de que el daño sea mayor. Los pulmones no avisan con dolor cuando se cicatrizan — la espirometría es la única forma de saberlo a tiempo. Continúe el azatioprina según lo indicado — si tiene preguntas sobre si es el momento de reducir la dosis, hablamos cuando venga a la próxima cita con la espirometría más reciente en mano.' (The spirometry we perform every six months is the way to know if the lung tissue is stable. As long as the number remains stable or improves, it is a sign that treatment is working. If the number falls — even if you do not feel a difference — it is the signal to adjust before the damage is greater. The lungs do not warn with pain when they scar — spirometry is the only way to know it in time. Continue azathioprine as directed — if you have questions about whether it is time to reduce the dose, we discuss when you come to the next appointment with the most recent spirometry in hand.)

November 4, 2026 · Rheumatology, Sjögren’s Syndrome, Extraglandular Manifestations

Spanish for Sjögren’s syndrome extraglandular manifestations clinic nurses — the patient who stopped hydroxychloroquine when dry eyes improved not knowing anti-Ro52/SSA complement activation at dorsal root ganglia continues destroying sensory neurons independent of glandular activity; the patient who stopped rituximab when anti-SSA titer fell not knowing the cryoglobulinemic B cell clone is a MALT-like IgM-kappa expansion that reconstitutes faster than mainstream B cells and drives cryoglobulinemic nephritis; and the patient who stopped azathioprine when anti-Ro52 titers fell and lung tests stabilized not knowing Sjögren’s ILD fibrosis is TGF-β myofibroblast driven and partially autonomous from antibody levels once established

Three conversations for Sjögren’s extraglandular manifestations clinic nurses: María Cisneros-Aguirre, 47, Houston, who stopped HCQ when Schirmer’s improved not knowing anti-Ro52/SSA complement destroys DRG sensory neurons in an anatomical compartment completely separate from the lacrimal gland; Ernesto Villanueva-Morales, 61, Miami, who stopped rituximab when anti-SSA fell not knowing the cryoglobulinemic IgM-kappa MALT-clone reconstitutes faster than mainstream B cells driving cryoglobulinemic nephritis; and Sofía Ramírez-Torres, 42, Chicago, who stopped azathioprine when anti-Ro52 titers fell and PFTs stabilized not knowing Sjögren’s NSIP fibrosis is TGF-β-myofibroblast driven and partially autonomous from antibody levels once established.

Primary Sjögren’s syndrome presents the extraglandular manifestations clinic nurse with a set of adherence challenges that are structurally different from those in the glandular clinic: the patient’s frame of reference for the disease is built entirely around dry eyes and dry mouth — the symptoms that brought them to diagnosis, the symptoms that responded to treatment, and the symptoms they monitor at home. The extraglandular organs — the dorsal root ganglia, the small vessels of the skin and kidney, the alveolar interstitium — provide no equivalent feedback. A sensory neuron destroyed by complement in the dorsal root ganglion sends no pain signal. A cryoglobulinemic B cell clone reconstituting in salivary gland MALT produces no early symptom. An alveolar myofibroblast depositing collagen in the lower lobes causes no dyspnea until FVC has fallen by fifteen to twenty percent. The patient who stops treatment because their glandular symptoms are under control is not making a reckless decision — they are making a reasonable inference from the only evidence their body provides. The nurse’s task is to give them evidence from the parts of their body that cannot speak for themselves.

Three patients, three extraglandular compartments, three distinct mechanistic pathways, and three conversations that require the nurse to explain anti-Ro52/SSA complement neurotoxicity at the dorsal root ganglion, the MALT-like clonal biology of Sjögren’s cryoglobulinemia, and the TGF-β myofibroblast fibrogenic axis in Sjögren’s ILD — in clinical Spanish that the patient can connect to their own treatment decisions.

Scenario 1: María Cisneros-Aguirre — 47 years old, Houston, Texas

María Cisneros-Aguirre was a forty-seven-year-old bilingual customer service supervisor in Houston who had been diagnosed with primary Sjögren’s syndrome two years before this visit. The diagnosis had come after she mentioned to her internist that her eyes had been dry and gritty for months — she was going through two bottles of artificial tears per week and waking up with her eyelids feeling stuck together. Blood work showed ANA titer one to six hundred and forty in a speckled pattern, anti-Ro52/SSA antibody one to six hundred and forty by ELISA confirmed on line immunoassay, anti-La/SSB one to eighty. Schirmer’s test was two millimeters bilaterally at five minutes indicating severe aqueous tear deficiency. Unstimulated whole salivary flow was 0.05 milliliters per minute. Labial salivary gland biopsy showed focal score 2.5 lymphocytic foci per four square millimeters, confirming primary Sjögren’s.

At the same diagnostic workup, the rheumatologist noted on the ESSDAI neurological domain: María had been noticing for eighteen months that the soles of her feet felt “thick” and “wrapped in plastic.” Vibration testing with a 128 Hz tuning fork was absent at both medial malleoli. Proprioception testing at the hallux was impaired bilaterally. Nerve conduction study confirmed sensory axonopathy in a pattern consistent with dorsal root ganglionopathy: sensory nerve action potential amplitudes were absent or severely reduced in the sural, superficial peroneal, and median sensory nerves bilaterally, with relatively preserved motor nerve conduction — the electromyographer’s note read “pattern consistent with sensory neuronopathy, consider autoimmune ganglionopathy.”

She was started on hydroxychloroquine four hundred milligrams daily and referred for IVIG evaluation for the neuropathy. At eighteen months on hydroxychloroquine, her Schirmer’s test had improved from two millimeters to six millimeters, artificial tear use dropped from twelve drops per eye per day to four, and she reported her eyes were comfortable for the first time in years. She came to the clinic today to tell nurse Elena Torres-Espinoza that she wanted to stop hydroxychloroquine.

“Mire, enfermera, mis ojos están bien por primera vez en años. No necesito las gotas casi nada. Siento que el medicamento hizo su trabajo y ya puedo dejarlo.”

(Look, nurse, my eyes are fine for the first time in years. I hardly need the drops at all. I feel like the medication did its work and I can now stop it.)

Nurse Torres-Espinoza recognized immediately that this reasoning — entirely accurate about the glandular benefit — missed the essential biology of what HCQ was doing in the dorsal root ganglia.

“María, me alegra mucho que sus ojos estén mejor — es una señal real de que el medicamento está funcionando. Pero quiero explicarle algo importante sobre por qué no podemos tomar esa decisión basándonos solo en los ojos.”

(María, I am very glad your eyes are better — it is a real sign that the medication is working. But I want to explain something important about why we cannot make that decision based only on the eyes.)

“¿Qué otra cosa hace el medicamento?”

“El hidroxicloroquina funciona bloqueando unos sensores dentro de las células del sistema inmune — se llaman TLR7 y TLR9. Esos sensores detectan el ARN que forma parte de los antígenos de su enfermedad, y cuando los detectan, producen una señal de alarma — interferón tipo I — que activa las células B para producir sus anticuerpos anti-Ro52. El hidroxicloroquina bloquea esos sensores y reduce la producción de los anticuerpos con el tiempo. Los ojos mejoran porque los anticuerpos atacan también las glándulas lagrimales, y al reducirse los anticuerpos, las glándulas trabajan mejor. Pero sus anticuerpos anti-Ro52 en su enfermedad hacen algo más que dañar las glándulas — y ese algo más está relacionado con sus nervios.”

(Hydroxychloroquine works by blocking sensors inside immune system cells — they are called TLR7 and TLR9. Those sensors detect the RNA that forms part of the antigens in your disease, and when they detect them, they produce an alarm signal — type I interferon — that activates B cells to produce your anti-Ro52 antibodies. Hydroxychloroquine blocks those sensors and reduces antibody production over time. The eyes improve because the antibodies also attack the lacrimal glands, and as antibodies are reduced, the glands work better. But your anti-Ro52 antibodies in your disease do something more than damage the glands — and that something more is related to your nerves.)

“¿Los nervios? ¿El hormigueo en los pies?”

“Exactamente. Los nervios sensoriales — los que le permiten sentir vibración, posición, temperatura — salen de unas neuronas que están junto a la columna vertebral. Se llaman ganglios de la raíz dorsal. Estos ganglios tienen algo que los hace especiales y vulnerables al mismo tiempo: no tienen la barrera de protección que tienen los nervios normales. Los nervios normales tienen una barrera de células muy apretadas que impide que las proteínas de la sangre lleguen a las neuronas. Los ganglios no tienen esa barrera — los vasos capilares son abiertos, como una esponja, y las proteínas de la sangre — incluyendo sus anticuerpos — llegan directamente a las neuronas.”

(Exactly. The sensory nerves — those that allow you to feel vibration, position, temperature — originate from neurons alongside the spinal column. They are called dorsal root ganglia. These ganglia have something that makes them special and vulnerable at the same time: they do not have the protective barrier that normal nerves have. Normal nerves have a barrier of very tightly packed cells that prevents blood proteins from reaching the neurons. The ganglia do not have that barrier — the capillary vessels are open, like a sponge, and blood proteins — including your antibodies — reach the neurons directly.)

María was listening carefully. “¿Y los anticuerpos pueden dañar esas neuronas?”

“Sí. Los anticuerpos anti-Ro52 se unen a la superficie de esas neuronas y activan el sistema de complemento — una cascada de proteínas del sistema inmune que, cuando se activa sobre una célula, forma un complejo que perfora la membrana de esa célula. Cuando ese complejo se forma en la neurona, la neurona muere. Y aquí está el problema: esas neuronas no se pueden regenerar. Cuando una neurona del ganglio dorsal muere, el nervio sensorial que salía de ella no puede ser reemplazado. La sensación que dependía de esa neurona — la vibración en el pie, la posición del dedo gordo — se pierde de manera permanente.”

(Yes. Anti-Ro52 antibodies bind to the surface of those neurons and activate the complement system — a cascade of immune system proteins that, when activated on a cell, forms a complex that perforates the membrane of that cell. When that complex forms on the neuron, the neuron dies. And here is the problem: those neurons cannot regenerate. When a dorsal ganglion neuron dies, the sensory nerve that emerged from it cannot be replaced. The sensation that depended on that neuron — the vibration in the foot, the position of the big toe — is lost permanently.)

“¿Y el medicamento puede proteger esas neuronas?”

“El medicamento puede proteger las que aún no se han dañado. No puede recuperar las que se perdieron — esas ya no vuelven. Pero al reducir los anticuerpos en la sangre, reduce la cantidad de anticuerpos que llegan a los ganglios y frena el proceso de destrucción en las neuronas que quedan. Las que ya se perdieron explican por qué todavía tiene el hormigueo y la pérdida de sensación en los pies — eso es el daño que ya ocurrió antes de empezar el tratamiento. El medicamento está frenando el daño adicional que ocurriría si los anticuerpos siguieran sin control.”

(The medication can protect the ones that have not yet been damaged. It cannot recover those that were lost — those do not return. But by reducing the antibodies in the blood, it reduces the number of antibodies that reach the ganglia and slows the process of destruction in the remaining neurons. The ones that were lost explain why you still have the tingling and sensation loss in the feet — that is the damage that already occurred before starting treatment. The medication is slowing the additional damage that would occur if the antibodies continued unchecked.)

“O sea, que aunque mis ojos estén mejor, los nervios siguen necesitando el medicamento.”

“Exactamente. Los ojos y los nervios son dos lugares distintos en el cuerpo, con mecanismos distintos. Los ojos mejoran porque las glándulas lagrimales se recuperaron un poco con la reducción de la inflamación local. Los nervios no mejoran cuando los anticuerpos bajan — porque las neuronas que se perdieron ya no se recuperan. Pero si paramos el medicamento, los anticuerpos vuelven a subir, y el proceso de destrucción en las neuronas que quedan se acelera. La pérdida de sensación puede extenderse hacia arriba — de los tobillos a las rodillas — y la pérdida de posición puede afectar el equilibrio hasta el punto de necesitar un bastón para caminar segura.”

(So, even though my eyes are better, the nerves still need the medication.) Exactly. The eyes and the nerves are two different locations in the body, with different mechanisms. The eyes improve because the lacrimal glands recovered somewhat with the reduction of local inflammation. The nerves do not improve when antibodies fall — because the neurons that were lost do not recover. But if we stop the medication, the antibodies rise again, and the destruction process in the remaining neurons accelerates. The sensation loss can extend upward — from ankles to knees — and the position loss can affect balance to the point of needing a cane to walk safely.)

María was quiet for a moment. “¿Cuánto tiempo tengo que seguir tomándolo?”

“En Sjögren’s con neuropatía, el hidroxicloroquina generalmente se mantiene indefinidamente, porque la enfermedad que daña las neuronas no remite sola. Lo revisamos en cada visita. Si hay cambios en la neuropatía o en la tolerancia al medicamento, lo discutimos con el reumatólogo. Pero la decisión de parar no se puede basar solo en que los ojos estén mejor.”

(In Sjögren’s with neuropathy, hydroxychloroquine is generally maintained indefinitely, because the disease that damages neurons does not remit on its own. We review it at each visit. If there are changes in the neuropathy or in tolerance to the medication, we discuss it with the rheumatologist. But the decision to stop cannot be based solely on the eyes being better.)

Scenario 2: Ernesto Villanueva-Morales — 61 years old, Miami, Florida

Ernesto Villanueva-Morales was a sixty-one-year-old retired postal worker in Miami who had been diagnosed with primary Sjögren’s syndrome four years earlier after presenting to his internist with palpable purpura on his lower legs. The internist had sent him to rheumatology after noticing the purpuric rash was non-blanching and bilateral. At rheumatology: anti-Ro52/SSA titer one to twelve hundred and eighty, anti-La/SSB one to one hundred and sixty, rheumatoid factor one to twelve hundred and eighty, cryoglobulin positive with cryocrit of twelve percent, immunofixation identifying IgM-kappa as the monoclonal component and polyclonal IgG in a type II mixed cryoglobulin pattern. Kidney function was mildly reduced: creatinine one point four milligrams per deciliter elevated from a baseline of zero point nine two years earlier; urinalysis showed two-plus proteinuria. Kidney biopsy confirmed membranoproliferative glomerulonephritis with IgM-kappa deposits and C3 along capillary loops — cryoglobulinemic nephritis.

He also had digital ulcers on the right index and middle fingers — small, painful, well-demarcated ulcerations on the digital pulps from ischemia in small vessels occluded by cryoglobulin deposition. The clinical picture was primary Sjögren’s syndrome complicated by type II mixed cryoglobulinemia with cryoglobulinemic leukocytoclastic vasculitis (purpura, digital ulcers) and membranoproliferative glomerulonephritis.

He was started on rituximab one thousand milligrams intravenously on days zero and fourteen as the induction course, then six-monthly maintenance infusions, plus hydroxychloroquine four hundred milligrams daily and low-dose prednisone ten milligrams daily. At nine months into rituximab treatment, anti-Ro52/SSA titer had fallen from one to twelve hundred and eighty to one to forty. The purpura had resolved. The digital ulcers had healed. He came in today to see nurse Patricia Cisneros-Fuentes to report he had decided to stop rituximab.

“Mire, el anticuerpo del Sjögren’s casi desapareció. Las manchas en las piernas están bien. Los dedos están bien. El reumátolo fue a verme hace tres semanas y me dijo que todo se ve bien. Yo creo que la enfermedad está curada y el rituximab ya hizo su trabajo.”

(Look, the Sjögren’s antibody has almost disappeared. The spots on the legs are fine. The fingers are fine. The rheumatologist saw me three weeks ago and told me everything looks good. I think the disease is cured and rituximab has done its work.)

Nurse Cisneros-Fuentes noted that the rheumatologist’s note from three weeks ago had not indicated stopping rituximab — it had noted excellent response with plan to continue six-monthly maintenance. This was a between-visit unilateral self-discontinuation.

“Ernesto, me alegra mucho que todo se vea bien — los anticuerpos bajando y la piel clara son señales de que el rituximab está funcionando. Pero quiero explicarle algo sobre cómo funciona la vasculitis en su Sjögren’s, porque es un poco más complicado que solo el anticuerpo anti-Ro52.”

(Ernesto, I am very glad that everything looks good — the falling antibodies and clear skin are signs that rituximab is working. But I want to explain something about how the vasculitis in your Sjögren’s works, because it is a bit more complicated than just the anti-Ro52 antibody.)

“¿Qué quiere decir?”

“El anti-Ro52 que bajó indica que el rituximab eliminó un grupo de células B que producen ese anticuerpo. Eso es bueno — esas células estaban activadas por la enfermedad y los anticuerpos anti-Ro52 contribuyen a la inflamación general del Sjögren’s. Pero la vasculitis — las manchas moradas, las úlceras en los dedos, el daño en el riñón — no la produce directamente el anti-Ro52. La produce un grupo diferente de células B.”

(The anti-Ro52 that fell indicates that rituximab eliminated a group of B cells that produce that antibody. That is good — those cells were activated by the disease and anti-Ro52 antibodies contribute to the general inflammation of Sjögren’s. But the vasculitis — the purple spots, the finger ulcers, the kidney damage — is not produced directly by anti-Ro52. It is produced by a different group of B cells.)

“¿Hay otro grupo?”

“Sí. En Sjögren’s, cuando las glándulas salivales se inflaman por años, el tejido linfoide dentro de las glándulas — el tejido donde están las células B — puede formar una especie de clon: un grupo de células B que se multiplican juntas y producen el mismo anticuerpo IgM-kappa — que es el que formó los crióglobulos en su sangre. Este clon no es exactamente igual que las demás células B del sistema inmune. Es como si se hubiera establecido en las glándulas con su propia lógica. Cuando el rituximab entra, elimina las células B normales muy bien — y eso hace bajar el anti-Ro52. Pero este clon puede tener células en diferentes etapas de desarrollo, algunas de las cuales no expresan la proteína CD20 que el rituximab necesita para reconocerlas. Esas células sobreviven más tiempo, y cuando el efecto del rituximab empieza a disminuir, el clon puede recuperarse más rápido que las células B normales.”

(Yes. In Sjögren’s, when the salivary glands are inflamed for years, the lymphoid tissue inside the glands — the tissue where B cells reside — can form a kind of clone: a group of B cells that multiply together and produce the same IgM-kappa antibody — which is the one that formed the cryoglobulins in your blood. This clone is not exactly the same as the other B cells of the immune system. It is as if it had established itself in the glands with its own logic. When rituximab enters, it eliminates normal B cells very well — and that makes anti-Ro52 fall. But this clone can have cells at different stages of development, some of which do not express the CD20 protein that rituximab needs to recognize them. Those cells survive longer, and when the effect of rituximab starts to diminish, the clone can recover faster than normal B cells.)

Ernesto leaned forward. “¿Y eso qué significa para mí?”

“Significa que el marcador del clon — el criocrito y el factor reumatoide — puede subir antes de que el anti-Ro52 suba. Si usted para el rituximab ahora porque el anti-Ro52 está bajo, el clon puede empezar a producir el IgM-kappa crióglobulo de nuevo — y ese crióglobulo es el que se deposita en los vasos del riñón, en los vasos de la piel. Si la glomerulopatia crióglobulínica se reactiva, el daño adicional en el riñón puede ser parcialmente permanente. Los glómerulos que se dañan en la reactivación no se recuperan cuando se reinicia el rituximab.”

(It means that the clone’s marker — the cryocrit and the rheumatoid factor — can rise before anti-Ro52 rises. If you stop rituximab now because anti-Ro52 is low, the clone can start producing IgM-kappa cryoglobulin again — and that cryoglobulin is what deposits in the vessels of the kidney, in the skin vessels. If cryoglobulinemic glomerulonephritis reactivates, the additional kidney damage can be partially permanent. The glomeruli that are damaged in the reactivation do not recover when rituximab is restarted.)

“¿Cuál es la señal de que el clon está volviendo?”

“En los análisis: que el factor reumatoide suba o que el criocrito suba — esos son los marcadores del clon. También si vuelven las manchas moradas en las piernas — si ve manchas no blanqueables en la piel, llame ese mismo día. Si sus dedos se ponen fríos o dolorosos con el frío de manera más intensa de lo habitual, llame. Si la creatinina sube en los próximos análisis, eso puede indicar que el riñón está bajo presión otra vez. Las infusiones de mantenimiento cada seis meses están diseñadas precisamente para mantener el clon bajo control antes de que se reactive.”

(In the tests: if rheumatoid factor rises or cryocrit rises — those are the clone’s markers. Also if the purple spots on the legs return — if you see non-blanching spots on the skin, call that same day. If your fingers become colder or more painful with cold than usual, call. If creatinine rises in the next tests, that may indicate the kidney is under pressure again. The maintenance infusions every six months are designed precisely to keep the clone under control before it reactivates.)

Ernesto agreed to continue the rituximab maintenance. He asked the nurse to call the rheumatologist to confirm, which she did that afternoon. The rheumatologist confirmed maintenance rituximab at the next scheduled infusion in six weeks.

Scenario 3: Sofía Ramírez-Torres — 42 years old, Chicago, Illinois

Sofía Ramírez-Torres was a forty-two-year-old bilingual social worker in Chicago who had been diagnosed with primary Sjögren’s syndrome and associated interstitial lung disease two years before this visit. The diagnosis had been made incidentally: a chest CT done for recurrent pneumonia had shown bilateral lower-lobe ground-glass opacities and reticular pattern in a basal-predominant subpleural distribution without honeycombing, consistent with nonspecific interstitial pneumonia on high-resolution CT. Full workup: ANA one to six hundred and forty speckled, anti-Ro52/SSA one to three hundred and twenty, anti-La/SSB one to forty, minor salivary gland biopsy focal score 2.0, Schirmer’s six millimeters bilaterally — mild glandular involvement. PFTs at diagnosis: FVC seventy-two percent predicted, DLCO sixty percent predicted — mild ILD with moderate diffusion impairment. No significant dry eyes or dry mouth symptoms; she had not been presenting to medical care for glandular Sjögren’s.

She was started on azathioprine one hundred and fifty milligrams daily and prednisone seven point five milligrams daily with PFTs every six months. At two years her anti-Ro52/SSA titer had fallen from one to three hundred and twenty to one to twenty. PFTs showed FVC seventy-three percent predicted and DLCO sixty-one percent — essentially stable over two years. HRCT chest showed no significant interval change. She had no respiratory symptoms. She came to the clinic to tell nurse Gabriela Espinoza-Cisneros she wanted to stop the azathioprine.

“Enfermera, el anticuerpo casi desapareció — de 1:320 a 1:20. Los pulmones están iguales. No tengo fáltame el aire. Me parece que ya la enfermedad está bajo control y ese medicamento tiene efectos secundarios que me preocupan — me hace sentir un poco náuseas y soy más susceptible a infecciones.”

(Nurse, the antibody has almost disappeared — from 1:320 to 1:20. The lungs are the same. I am not short of breath. It seems to me the disease is under control and that medication has side effects that concern me — it makes me feel a bit nauseated and I am more susceptible to infections.)

Nurse Espinoza-Cisneros listened carefully. The side effect concerns were real and warranted a conversation with the rheumatologist about dose adjustment. But the reasoning for stopping — antibody near-normalized + stable PFTs — reflected a misunderstanding of what azathioprine was doing in Sjögren’s ILD.

“Sofía, los efectos secundarios son algo que podemos revisar con el reumatólogo — es una conversación válida y hay veces en que se puede ajustar la dosis. Pero primero quiero explicarle por qué la estabilidad de la espirometría y el anticuerpo bajo son precisamente la señal de que el medicamento está funcionando — no de que se puede parar.”

(Sofía, the side effects are something we can review with the rheumatologist — it is a valid conversation and sometimes the dose can be adjusted. But first I want to explain why spirometry stability and low antibody are precisely the sign that the medication is working — not that it can be stopped.)

“¿No es lo mismo?”

“No. El azatioprina funciona bloqueando una enzima en los linfocitos — se llama IMDH — que hace que los linfocitos no puedan multiplicarse. Bloquea tanto las células B como las células T. Las células B son las que producen el anticuerpo anti-Ro52, y al bloquearse, el anticuerpo baja — eso es lo que usted ve en los análisis. Pero las células T son las que llegan a los pulmones y activan los macrófagos para que produzcan TGF-beta, que es la señal que convierte células normales del tejido pulmonar en células cicatriciales llamadas miofibroblastos. Los miofibroblastos depositan colágeno y reducen la capacidad del pulmón — eso es lo que hace bajar la FVC y la DLCO.”

(No. Azathioprine works by blocking an enzyme in lymphocytes — called IMDH — that prevents lymphocytes from multiplying. It blocks both B cells and T cells. B cells are the ones that produce the anti-Ro52 antibody, and when blocked, the antibody falls — that is what you see in the tests. But T cells are the ones that travel to the lungs and activate macrophages to produce TGF-beta, which is the signal that converts normal lung tissue cells into scar cells called myofibroblasts. Myofibroblasts deposit collagen and reduce lung capacity — that is what makes FVC and DLCO fall.)

“¿Y eso no para cuando el anticuerpo baja?”

“Aquí está la parte clave: los miofibroblastos que ya están en el pulmón — los que se formaron antes de que empezara el tratamiento — producen su propia señal TGF-beta de manera casi independiente. Se llama autocrina porque la célula produce la señal para sí misma. Mientras el azatioprina esté activo, las células T no llegan al pulmón en cantidades suficientes para activar más macrófagos, y esa autocrina está relativamente controlada. Si para el azatioprina, las células T vuelven al pulmón — y vuelven antes de que el anticuerpo anti-Ro52 suba de nuevo, porque la recuperación de las células T es más rápida que la recuperación de las células B productoras de anticuerpos. Cuando las células T vuelven, activan más macrófagos, que producen más TGF-beta, que alimenta los miofibroblastos que ya estaban, y la FVC y la DLCO empiezan a caer.”

(Here is the key part: the myofibroblasts already in the lung — those that formed before treatment started — produce their own TGF-beta signal almost independently. It is called autocrine because the cell produces the signal for itself. While azathioprine is active, T cells do not reach the lung in sufficient numbers to activate more macrophages, and that autocrine signaling is relatively controlled. If you stop azathioprine, T cells return to the lung — and they return before anti-Ro52 rises again, because T cell recovery is faster than the recovery of antibody-producing B cells. When T cells return, they activate more macrophages, which produce more TGF-beta, which feeds the myofibroblasts already there, and FVC and DLCO begin to fall.)

“¿Y si la DLCO cae un poco y luego reinicio el medicamento, se recupera?”

“No. Eso es lo importante. El colágeno que depositan los miofibroblastos durante el período sin tratamiento es permanente — no se rehace. Cuando reiniciamos el azatioprina, podemos parar que el daño continúe, pero la función pulmonar que se perdió durante ese período no vuelve. La espirometría que está estable ahora en 73% de FVC — eso es lo que el azatioprina está protegiendo. La meta es que ese número no caiga. Parar el medicamento pone ese número en riesgo.”

(No. That is the important part. The collagen deposited by myofibroblasts during the treatment-free period is permanent — it is not remade. When we restart azathioprine, we can stop the damage from continuing, but the lung function lost during that period does not return. The spirometry that is stable now at 73% FVC — that is what azathioprine is protecting. The goal is for that number not to fall. Stopping the medication puts that number at risk.)

Sofía was thoughtful. “¿Y los efectos secundarios?”

“Podemos revisarlos con el reumatólogo en la próxima visita. A veces se puede bajar la dosis gradualmente si la función pulmonar ha estado estable por más tiempo. Pero la decisión de reducir o parar tiene que basarse en la estabilidad de los pulmones a lo largo del tiempo — no solo en que el anticuerpo bajó. ¿Le parece bien que hablemos de esto con el doctor juntos?”

(We can review them with the rheumatologist at the next visit. Sometimes the dose can be gradually reduced if lung function has been stable for longer. But the decision to reduce or stop must be based on lung stability over time — not just that the antibody fell. Does it seem all right to you that we discuss this with the doctor together?)

Key Spanish phrases for Sjögren’s extraglandular manifestations clinic nurses

For peripheral sensory ganglionopathy

Explaining why HCQ must continue after glandular improvement in patients with neuropathy:
“El hidroxicloroquina está protegiendo los nervios sensoriales, no solo los ojos. Los anticuerpos anti-Ro52 en su enfermedad pueden dañar las neuronas de los ganglios de la raíz dorsal — grupos de neuronas junto a la columna vertebral sin barrera de protección normal. Cuando esas neuronas mueren, no se recuperan. El medicamento reduce los anticuerpos en la sangre y frena ese proceso. Que sus ojos mejoren no significa que esas neuronas estén protegidas sin el medicamento.”

Monitoring signs of neuropathy progression:
“Si nota que siente menos vibración o temperatura en los pies, o que el balance empeora al caminar en la oscuridad, o que necesita ver el suelo mientras camina para no tropezar, llame a la clínica ese día. Si al cerrar los ojos de pie siente que se va a caer, llame de inmediato.”

For cryoglobulinemic vasculitis

Explaining why rituximab must continue after anti-SSA titer falls:
“El anticuerpo anti-SSA bajo indica que un grupo de células B está controlado. Pero la vasculitis viene de un clon diferente — uno que produce IgM-kappa. Ese clon puede recuperarse más rápido que las demás células B, incluso cuando el anti-SSA sigue bajo. Por eso seguimos el criocrito y el factor reumatoide para vigilar la vasculitis — no el anti-SSA. Las infusiones de mantenimiento cada seis meses controlan ese clon.”

Monitoring signs of cryoglobulinemic relapse:
“Si aparecen manchas moradas en las piernas que no blanquean al presionarlas, llame ese día. Si los dedos de manos o pies se ponen oscuros, fríos o dolorosos con el frío, llame. Si la creatinina sube o hay proteína nueva en la orina, es urgente.”

For Sjögren’s ILD

Explaining why azathioprine must continue after anti-Ro52 titers fall in ILD:
“El anticuerpo bajo significa que el azatioprina está funcionando. Pero el daño en el pulmón no lo producen los anticuerpos directamente — lo producen las células T que activan macrófagos que producen TGF-beta que forma cicatriz. Las células T vuelven al pulmón más rápido que el anticuerpo sube si para el medicamento. Y la función pulmonar que se pierde en ese período no se recupera.”

Explaining the PFT surveillance schedule:
“La espirometría cada seis meses es la única forma de saber si el pulmón está estable — los pulmones no avisan con dolor cuando se cicatrizan. Si el número cae, aunque no sienta nada diferente, es la señal para ajustar el tratamiento antes de que el daño sea mayor.”

For foundational Spanish for the Sjögren’s syndrome glandular clinic, see Spanish for Sjögren’s syndrome clinic nurses, covering HCQ and lymphoma risk, pilocarpine and acinar cell biology, and potassium supplementation in Sjögren’s renal tubular acidosis. For Spanish in the cryoglobulinemic vasculitis clinic more broadly, see Spanish for cryoglobulinemic vasculitis clinic nurses. For Spanish in the rheumatology clinic covering multiple connective tissue diseases, see Spanish for rheumatology clinic nurses and Spanish for mixed connective tissue disease clinic nurses.